Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 14/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 14/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 13/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL536741 | 0.86 | ADORA2A (0.43) | PARP1ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL21814677 | 0.78 | ADORA2A (0.44) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL21814389 | 0.77 | ADORA2A (0.43) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL536775 | 0.75 | CNR2 (0.43) | ADORA2AADORA2BADORA1ADORA3CNR2 | |
| SCHEMBL29980893 | 0.75 | CNR2 (0.43) | ADORA2AADORA2BADORA1ADORA3CNR2 | |
| SCHEMBL536819 | 0.75 | CNR2 (0.43) | ADORA2AADORA2BADORA1ADORA3CNR2 | |
| SCHEMBL536686 | 0.74 | ADORA2A (0.47) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL27808306 | 0.73 | PARP1 (0.49) | PARP1PDE10ACNR2PIM1PIM3 | |
| SCHEMBL3389598 | 0.73 | ADORA2A (0.64) | ADORA2AADORA2BADORA1ADORA3LMNA | |
| SCHEMBL537311 | 0.72 | ADORA2A (0.41) | ADORA2AADORA2BADORA1ADORA3CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230100842-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | LIGAND UK DEVELOPMENT LIMITED (GB) | 2023-03-30 | — | — | US | disclosed |
| US-11466019-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2022-10-11 | — | — | US | disclosed |
| US-20210115054-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2021-04-22 | — | — | US | disclosed |
| US-10875868-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2020-12-29 | — | — | US | disclosed |
| US-20200172547-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
| US-10538526-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2020-01-21 | — | — | US | disclosed |
| US-20190031668-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| US-10106547-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2018-10-23 | — | — | US | disclosed |
| US-20170342081-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2017-11-30 | — | — | US | disclosed |
| US-9765080-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2017-09-19 | — | — | US | disclosed |
| US-20170088552-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2017-03-30 | — | — | US | disclosed |
| US-9376443-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2016-06-28 | — | — | US | disclosed |
| US-20150291602-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS (R&D) LIMITED (GB) | 2015-10-15 | — | — | US | disclosed |
| US-8987279-B2 | Triazolo [4, 5-D] pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2015-03-24 | — | — | US | disclosed |
| US-20130245044-A1 | TRIAZOLO[4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2013-09-19 | — | — | US | disclosed |
| US-8450328-B2 | Triazolo[4,5-D]pyramidine derivatives and their use as purine receptor antagonists | VERNALIS (R&D) LIMITED (GB) | 2013-05-28 | — | — | US | disclosed |
| EP-2321321-B1 | TRIAZOLO [4, 5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS R&D LTD (GB) | 2012-02-08 | — | — | EP | disclosed |
| US-20110172252-A1 | TRIAZOLO[4,5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10106547-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | PARP1 894/4885ADORA2A 11/4885ADORA2B 19/4885 |
| US-20110172252-A1 | TRIAZOLO[4,5-D]PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | PARP1 894/4885ADORA2A 11/4885ADORA2B 19/4885 |
| US-20170342081-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | PARP1 894/4885ADORA2A 11/4885ADORA2B 19/4885 |
| US-20190031668-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | PARP1 894/4885ADORA2A 11/4885ADORA2B 19/4885 |
| US-20170088552-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | PARP1 842/4885ADORA2A 11/4885ADORA2B 19/4885 |
| US-10875868-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | PARP1 842/4885ADORA2A 11/4885ADORA2B 19/4885 |
| US-20210115054-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | PARP1 894/4885ADORA2A 11/4885ADORA2B 19/4885 |
| US-10538526-B2 | Triazolo[4,5-D] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | PARP1 894/4885ADORA2A 11/4885ADORA2B 19/4885 |
| US-20150291602-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | PARP1 842/4885ADORA2A 11/4885ADORA2B 19/4885 |
| US-20130245044-A1 | TRIAZOLO[4, 5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | PARP1 894/4885ADORA2A 11/4885ADORA2B 19/4885 |
| US-11466019-B2 | Triazolo[4,5-d] pyramidine derivatives and their use as purine receptor antagonists | P2RX5, P2RY1, P2RX3 | PARP1 894/4885ADORA2A 11/4885ADORA2B 19/4885 |
| US-20230100842-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | PARP1 894/4885ADORA2A 11/4885ADORA2B 19/4885 |
| US-20200172547-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | PARP1 842/4885ADORA2A 11/4885ADORA2B 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.